Cost per infection averted or per severe, critical, or fatal COVID-19 case averted during the pre-omicron phase (A and B, respectively) and during the omicron phase (C and D, respectively).
figure
posted on 2025-09-26, 17:38 authored by Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Asmaa A. Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al-Kuwari, Adeel A. Butt, Hamad Eid Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Laith J. Abu-Raddad<p>Cost per infection averted or per severe, critical, or fatal COVID-19 case averted during the pre-omicron phase (A and B, respectively) and during the omicron phase (C and D, respectively).</p>
History
Related Materials
Usage metrics
Keywords
sensitivity analyses confirmedmultiple coexisting conditionscoronavirus disease 2019146 -$ 881 &# 82114 &# 8211189 -$ 4targeted vaccination strategieshealth economic modelingadjusted life yearsseries vaccination incurredseries vaccination campaignprevent one infectionmoderate vaccine effectivenessindividuals &# 8805direct medical costs19 outcome avertedper severe covid19 mrna primaryvaccination remained costseries vaccinationmedical costs19 outcome4 individualssevere covidremained essentialeconomic evaluation50 years19 formsstudy aimedseptember 18retrospectively evaluateqalys ),omicron waveomicron phasenumber neededmass primaryjanuary 5integrated epidemiologicalincremental costeffectiveness ratiodetermined usingadditional cost7 qalys354 ).
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC